UVM Reference Number: C761
Summary:
Antibodies are highly capable of initiating cytotoxicity of target cells, but a fundamental unresolved property of antibody treatment of cancer is the heterogeneity of the cancer cell population of the tumor, and subsequent tumor resistance to the treatment. Using multiple cell surface related neo-antigens, each with a single amino-acid change, a cocktail of polyclonal antibodies was developed to address this target heterogeneity and redirect effector immune cells to multiple cancer cell types within the tumor.
Preliminary in vivo data shows intense and homogenous antibody binding with the pooled antibodies that, in combination with a PD1 inhibitor, prevents tumor growth in 50% of mice. In addition, this response was durable and rendered the responsive mice fully resistant to subsequent tumor challenge. Additional studies have shown that arming effector cells with the pooled antibodies and treating the mice with the armed effector cells and a PD1 inhibitor is similarly effective and reduces the amount of pooled antibodies needed significantly. Current work is establishing the selective criteria for the pooled antibodies and defining the immune effector cell population that provides the greatest tumor inhibition.
Applications:
- Broad spectrum cancer treatment
Advantages:
- Pooled antibodies overcome tumor cell type heterogeneity
- Requires 100-1000 times less antibodies
- Durable and resistant therapeutic response
- If it does arise, resistance can be overcome with new pool of antibodies
Reference:
AACR abstract: https://www.abstractsonline.com/pp8/#!/6812/presentation/2453
Opportunity:
- Looking for both licensing and industry partners for product development
Patents:
- US Patent No. 17/433,982
- Patent Cooperation Treaty PCT/US20/19867
Seeking:
- Licensing
- Development partner
